InvestorsHub Logo
Followers 16
Posts 4650
Boards Moderated 0
Alias Born 08/11/2015

Re: None

Monday, 08/14/2017 9:07:23 PM

Monday, August 14, 2017 9:07:23 PM

Post# of 18220
AND the good news (from today's 10-q)...

"Basic and diluted loss per share attributable to common shareholders" = 0.00

Someone please correct me if I'm wrong, but I'm ALMOST CERTAIN that Q2 2017 was now the FIRST TIME Immune Therapeutics did NOT record a LOSS PER SHARE over a 3 month period (due to a gain on settlement of debt).

And to do that WITHOUT revenue is a great sign. We are on the right track.